Pathogenesis and clinical features of psoriasis (Q36894005)

16 August 2017

1 reference

title

Pathogenesis and clinical features of psoriasis (English)

1 reference

16 August 2017

0 references

Christopher E M Griffiths

series ordinal

1

1 reference

PubMed ID

17658397

16 August 2017

Jonathan N W N Barker

series ordinal

2

1 reference

PubMed ID

17658397

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

370

1 reference

16 August 2017

263-271

1 reference

16 August 2017

9583

1 reference

The effect of severe psoriasis on the quality of life of 369 patients.

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

A classification of psoriasis vulgaris according to phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

How Great Is the Risk of Further Psoriasis Following a Single Episode of Acute Guttate Psoriasis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

1 reference

7 January 2021

Classification and diagnostic criteria for psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Prevalence of joint disease in patients with psoriasis: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

The natural history of psoriasis in 5,600 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Disease concomitance in psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Prevalence of cardiovascular risk factors in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

An Italian study on psoriasis and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

The Risk of Lymphoma in Patients with Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

The prevalence of malignant tumors in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Risk of Myocardial Infarction in Patients With Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Microcirculation in Psoriatic Skin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis: dysregulation of innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Inflammatory skin diseases, T cells, and immune surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis in Swedish conscripts: time trend and association with T-helper 2-mediated disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis occurring after myeloablative therapy and autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Clearance of severe psoriasis after allogenic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Innate and adaptive immunity and the pathophysiology of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Skin innate immune system in psoriasis: friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Cytokines and Langerhans cell mobilisation in mouse and man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Impaired Langerhans cell migration in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Endogenous antimicrobial peptides and skin infections in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Natural history of psoriasis in 61 twin pairs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

The pathophysiology of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

An update on the genetics of psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Fine Mapping of the PSORS4 Psoriasis Susceptibility Region on Chromosome 1q21

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Searching for the major histocompatibility complex psoriasis susceptibility gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

HCR, a candidate gene for psoriasis, is expressed differently in psoriasis and other hyperproliferative skin disorders and is downregulated by interferon-gamma in keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Association of TNF -238 and -308 Promoter Polymorphisms with Psoriasis Vulgaris and Psoriatic Arthritis but not with Pustulosis Palmoplantaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Dermal injection of immunocytes induces psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis-an index of disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Patients' strategies for coping with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Divergent beliefs about psoriasis are associated with increased psychological distress.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961128-3

7 January 2021

10.1016/S0140-6736(07)61128-3

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17658397